Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): Formulation development, characterization and pharmacological evaluation

Siddharth S. Kesharwani, Rizwan Ahmad, Mohammed Ali Bakkari, Mrigendra K.S. Rajput, Rakesh Dachineni, Chaitanya K. Valiveti, Saurabh Kapur, G. Jayarama Bhat, Amar B. Singh, Hemachand Tummala

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Inflammatory Bowel Diseases (IBD) is a debilitating condition that affects ~70,000 new people every year and has been described as “an expensive disease with no known cure”. In addition, IBD increases the risk of developing colon cancer. The current therapeutics for IBD focus on the established disease where the immune dysfunction and bowel damage have already occurred but do not prevent or delay the progression. The current work describes a polymer-based anti-inflammatory technology (Ora-Curcumin-S) specifically targeted to the luminal side of the colon for preventing and/or treating IBD. Ora-Curcumin-S was prepared by molecular complexation of curcumin with a hydrophilic polymer Eudragit® S100 using co-precipitation method. Curcumin interacted with the polymer non-covalently and existed in an amorphous state as demonstrated by various physicochemical techniques. Ora-Curcumin-S is a polymer-drug complex, which is different than solid dispersions in that the interactions are retained even after dissolving in aqueous buffers. Ora-Curcumin-S was >1000 times water soluble than curcumin and importantly, the enhanced solubility was pH-dependent, which was observed only at pHs above 6.8. In addition, around 90% of Ora-Curcumin-S was stable in phosphate buffer, pH 7.4 and simulated intestinal fluid after 24 h, in contrast to 10–20% unformulated curcumin. Ora-Curcumin-S inhibited Monophosphoryl Lipid-A and E. coli induced inflammatory responses in dendritic cells and cells over expressing Toll-Like Receptor-4 (TLR-4) suggesting that Ora-Curcumin-S is a novel polymer-based TLR-4 antagonist. Preliminary pharmacokinetics in mice showed targeted delivery of soluble curcumin to the colon lumen without exposing to the systemic circulation. Furthermore, Ora-Curcumin-S significantly prevented colitis and associated injury in a mouse model of ulcerative colitis estimated using multiple preclinical parameters: colonoscopy pictures, body weight, colon length, colon edema, spleen weight, pro-inflammatory signaling and independent pathological scoring. Overall, the outcome of this innovative proof-of-concept study provides an exciting and locally-targeted pathway for a dietary therapeutic option for IBD patients to help limit colonic inflammation and thus susceptibility to colitis-associated colorectal cancer.

Original languageEnglish (US)
Pages (from-to)165-179
Number of pages15
JournalJournal of Controlled Release
Volume290
DOIs
StatePublished - Nov 28 2018

Fingerprint

Curcumin
Inflammatory Bowel Diseases
Polymers
Pharmacology
Pharmaceutical Preparations
Colon
Toll-Like Receptor 4
Colitis
Buffers
Immune System Diseases
Colonoscopy
Ulcerative Colitis
Solubility
Colonic Neoplasms
Dendritic Cells
Colorectal Neoplasms
Edema
Anti-Inflammatory Agents
Spleen

Keywords

  • Curcumin
  • Inflammatory bowel disease
  • Polymer-drug complexes
  • Site specific delivery
  • Solubility & stability
  • Toll-like Receptor-4

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD) : Formulation development, characterization and pharmacological evaluation. / Kesharwani, Siddharth S.; Ahmad, Rizwan; Bakkari, Mohammed Ali; Rajput, Mrigendra K.S.; Dachineni, Rakesh; Valiveti, Chaitanya K.; Kapur, Saurabh; Jayarama Bhat, G.; Singh, Amar B.; Tummala, Hemachand.

In: Journal of Controlled Release, Vol. 290, 28.11.2018, p. 165-179.

Research output: Contribution to journalArticle

Kesharwani, Siddharth S. ; Ahmad, Rizwan ; Bakkari, Mohammed Ali ; Rajput, Mrigendra K.S. ; Dachineni, Rakesh ; Valiveti, Chaitanya K. ; Kapur, Saurabh ; Jayarama Bhat, G. ; Singh, Amar B. ; Tummala, Hemachand. / Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD) : Formulation development, characterization and pharmacological evaluation. In: Journal of Controlled Release. 2018 ; Vol. 290. pp. 165-179.
@article{dc6f66113444400f8198188e7879df9e,
title = "Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD): Formulation development, characterization and pharmacological evaluation",
abstract = "Inflammatory Bowel Diseases (IBD) is a debilitating condition that affects ~70,000 new people every year and has been described as “an expensive disease with no known cure”. In addition, IBD increases the risk of developing colon cancer. The current therapeutics for IBD focus on the established disease where the immune dysfunction and bowel damage have already occurred but do not prevent or delay the progression. The current work describes a polymer-based anti-inflammatory technology (Ora-Curcumin-S) specifically targeted to the luminal side of the colon for preventing and/or treating IBD. Ora-Curcumin-S was prepared by molecular complexation of curcumin with a hydrophilic polymer Eudragit{\circledR} S100 using co-precipitation method. Curcumin interacted with the polymer non-covalently and existed in an amorphous state as demonstrated by various physicochemical techniques. Ora-Curcumin-S is a polymer-drug complex, which is different than solid dispersions in that the interactions are retained even after dissolving in aqueous buffers. Ora-Curcumin-S was >1000 times water soluble than curcumin and importantly, the enhanced solubility was pH-dependent, which was observed only at pHs above 6.8. In addition, around 90{\%} of Ora-Curcumin-S was stable in phosphate buffer, pH 7.4 and simulated intestinal fluid after 24 h, in contrast to 10–20{\%} unformulated curcumin. Ora-Curcumin-S inhibited Monophosphoryl Lipid-A and E. coli induced inflammatory responses in dendritic cells and cells over expressing Toll-Like Receptor-4 (TLR-4) suggesting that Ora-Curcumin-S is a novel polymer-based TLR-4 antagonist. Preliminary pharmacokinetics in mice showed targeted delivery of soluble curcumin to the colon lumen without exposing to the systemic circulation. Furthermore, Ora-Curcumin-S significantly prevented colitis and associated injury in a mouse model of ulcerative colitis estimated using multiple preclinical parameters: colonoscopy pictures, body weight, colon length, colon edema, spleen weight, pro-inflammatory signaling and independent pathological scoring. Overall, the outcome of this innovative proof-of-concept study provides an exciting and locally-targeted pathway for a dietary therapeutic option for IBD patients to help limit colonic inflammation and thus susceptibility to colitis-associated colorectal cancer.",
keywords = "Curcumin, Inflammatory bowel disease, Polymer-drug complexes, Site specific delivery, Solubility & stability, Toll-like Receptor-4",
author = "Kesharwani, {Siddharth S.} and Rizwan Ahmad and Bakkari, {Mohammed Ali} and Rajput, {Mrigendra K.S.} and Rakesh Dachineni and Valiveti, {Chaitanya K.} and Saurabh Kapur and {Jayarama Bhat}, G. and Singh, {Amar B.} and Hemachand Tummala",
year = "2018",
month = "11",
day = "28",
doi = "10.1016/j.jconrel.2018.08.004",
language = "English (US)",
volume = "290",
pages = "165--179",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",

}

TY - JOUR

T1 - Site-directed non-covalent polymer-drug complexes for inflammatory bowel disease (IBD)

T2 - Formulation development, characterization and pharmacological evaluation

AU - Kesharwani, Siddharth S.

AU - Ahmad, Rizwan

AU - Bakkari, Mohammed Ali

AU - Rajput, Mrigendra K.S.

AU - Dachineni, Rakesh

AU - Valiveti, Chaitanya K.

AU - Kapur, Saurabh

AU - Jayarama Bhat, G.

AU - Singh, Amar B.

AU - Tummala, Hemachand

PY - 2018/11/28

Y1 - 2018/11/28

N2 - Inflammatory Bowel Diseases (IBD) is a debilitating condition that affects ~70,000 new people every year and has been described as “an expensive disease with no known cure”. In addition, IBD increases the risk of developing colon cancer. The current therapeutics for IBD focus on the established disease where the immune dysfunction and bowel damage have already occurred but do not prevent or delay the progression. The current work describes a polymer-based anti-inflammatory technology (Ora-Curcumin-S) specifically targeted to the luminal side of the colon for preventing and/or treating IBD. Ora-Curcumin-S was prepared by molecular complexation of curcumin with a hydrophilic polymer Eudragit® S100 using co-precipitation method. Curcumin interacted with the polymer non-covalently and existed in an amorphous state as demonstrated by various physicochemical techniques. Ora-Curcumin-S is a polymer-drug complex, which is different than solid dispersions in that the interactions are retained even after dissolving in aqueous buffers. Ora-Curcumin-S was >1000 times water soluble than curcumin and importantly, the enhanced solubility was pH-dependent, which was observed only at pHs above 6.8. In addition, around 90% of Ora-Curcumin-S was stable in phosphate buffer, pH 7.4 and simulated intestinal fluid after 24 h, in contrast to 10–20% unformulated curcumin. Ora-Curcumin-S inhibited Monophosphoryl Lipid-A and E. coli induced inflammatory responses in dendritic cells and cells over expressing Toll-Like Receptor-4 (TLR-4) suggesting that Ora-Curcumin-S is a novel polymer-based TLR-4 antagonist. Preliminary pharmacokinetics in mice showed targeted delivery of soluble curcumin to the colon lumen without exposing to the systemic circulation. Furthermore, Ora-Curcumin-S significantly prevented colitis and associated injury in a mouse model of ulcerative colitis estimated using multiple preclinical parameters: colonoscopy pictures, body weight, colon length, colon edema, spleen weight, pro-inflammatory signaling and independent pathological scoring. Overall, the outcome of this innovative proof-of-concept study provides an exciting and locally-targeted pathway for a dietary therapeutic option for IBD patients to help limit colonic inflammation and thus susceptibility to colitis-associated colorectal cancer.

AB - Inflammatory Bowel Diseases (IBD) is a debilitating condition that affects ~70,000 new people every year and has been described as “an expensive disease with no known cure”. In addition, IBD increases the risk of developing colon cancer. The current therapeutics for IBD focus on the established disease where the immune dysfunction and bowel damage have already occurred but do not prevent or delay the progression. The current work describes a polymer-based anti-inflammatory technology (Ora-Curcumin-S) specifically targeted to the luminal side of the colon for preventing and/or treating IBD. Ora-Curcumin-S was prepared by molecular complexation of curcumin with a hydrophilic polymer Eudragit® S100 using co-precipitation method. Curcumin interacted with the polymer non-covalently and existed in an amorphous state as demonstrated by various physicochemical techniques. Ora-Curcumin-S is a polymer-drug complex, which is different than solid dispersions in that the interactions are retained even after dissolving in aqueous buffers. Ora-Curcumin-S was >1000 times water soluble than curcumin and importantly, the enhanced solubility was pH-dependent, which was observed only at pHs above 6.8. In addition, around 90% of Ora-Curcumin-S was stable in phosphate buffer, pH 7.4 and simulated intestinal fluid after 24 h, in contrast to 10–20% unformulated curcumin. Ora-Curcumin-S inhibited Monophosphoryl Lipid-A and E. coli induced inflammatory responses in dendritic cells and cells over expressing Toll-Like Receptor-4 (TLR-4) suggesting that Ora-Curcumin-S is a novel polymer-based TLR-4 antagonist. Preliminary pharmacokinetics in mice showed targeted delivery of soluble curcumin to the colon lumen without exposing to the systemic circulation. Furthermore, Ora-Curcumin-S significantly prevented colitis and associated injury in a mouse model of ulcerative colitis estimated using multiple preclinical parameters: colonoscopy pictures, body weight, colon length, colon edema, spleen weight, pro-inflammatory signaling and independent pathological scoring. Overall, the outcome of this innovative proof-of-concept study provides an exciting and locally-targeted pathway for a dietary therapeutic option for IBD patients to help limit colonic inflammation and thus susceptibility to colitis-associated colorectal cancer.

KW - Curcumin

KW - Inflammatory bowel disease

KW - Polymer-drug complexes

KW - Site specific delivery

KW - Solubility & stability

KW - Toll-like Receptor-4

UR - http://www.scopus.com/inward/record.url?scp=85055199542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055199542&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2018.08.004

DO - 10.1016/j.jconrel.2018.08.004

M3 - Article

C2 - 30142410

AN - SCOPUS:85055199542

VL - 290

SP - 165

EP - 179

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -